What it is
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist. The catalog source spells one SKU 'Tirzepetide'; the scientific identity is Tirzepatide.
Mechanism and research questions
- It activates GIP and GLP-1 receptor pathways.
- Clinical outcomes depend on the approved product, indication, dose-escalation schedule, and patient selection.
Human evidence
Published trials show substantial weight reduction in defined populations; the FDA label contains the authoritative approved-use and safety framework.
Preclinical / mechanistic evidence
Receptor pharmacology and molecular identity are documented in chemical and regulatory sources.
Evidence summary
SURMOUNT-1 was a 72-week randomized Phase 3 obesity trial; FDA labeling provides approved-product indications and warnings.
Limits and interpretation
- Approved-product evidence does not establish equivalence of a research vial.
- The FDA label must be read in full for contraindications and warnings.
- No dosing or medical-use advice is provided here.
Regulatory and identity note
Tirzepatide has FDA-approved products for specific indications; this catalog item remains research-use material.
Use Tirzepatide as the canonical identity. Keep the source-sheet spelling as an alias only so the catalog stays traceable without publishing a false scientific name.